Table 2 Patient characteristics of patients undergoing completion lymph node dissection due to positive SLN biopsy (cohort 2) and overall survival (OS) N = 473
Parameter | Value | N (%) | 5-year OS | 95 % CI | 8-year OS | 95 % CI | p value log-rank test |
|---|---|---|---|---|---|---|---|
Sex | Female | 235 (49.6 %) | 63.0 | (56.4–70.5) | 59.1 | (52.1–67.0) | 0.032 |
Male | 238 (50.4 %) | 51.2 | (44.2–59.4) | 44.8 | (37.3–53.9) | ||
Tumor type | NM | 264 | 57.2 | (50.6–64.6) | 51.0 | (44.1–59.1) | 0.006 |
SSM | 96 | 63.8 | (53.7–75.8) | 61.1 | (50.5–74.1) | ||
ALM | 15 | 20.0 | (6.3–63.8) | 20.0 | (6.3–63.8) | ||
LMM | 16 | 46.1 | (25.2–84.3) | 46.1 | (25.2–84.3) | ||
Other | 2 | 100.0 | (100.0–100.0) | 100.0 | (100.0–100.0) | ||
NA | 80 | 58.7 | (47.4–72.7) | 54.0 | (42.3–68.9) | ||
Clark level | II | 29 | 49.4 | (31.7–77.1) | 43.2 | (25.8–72.4) | 0.068 |
III | 154 | 69.8 | (62.2–78.4) | 61.4 | (52.1–72.4) | ||
IV | 206 | 51.9 | (44.2–60.9) | 50.8 | (43.1–59.9) | ||
V | 64 | 46.3 | (34.8–61.5) | 39.6 | (28.3–55.3) | ||
NA | 20 | 63.6 | (43.8–92.3) | 56.5 | (36.5–87.6) | ||
Presence of ulceration of primary tumor | No | 143 | 73.2 | (65.0–82.3) | 68.4 | (59.5–78.7) | 0.000 |
Yes | 293 | 49.0 | (42.7–56.1) | 43.8 | (37.3–51.4) | ||
NA | 37 | 60.9 | (45.7–81.4) | 57.1 | (41.7–78.3) | ||
Extracapsular involvement of sentinel node metastases | No | 363 | 58.5 | (53.0–64.7) | 52.7 | (46.8–59.4) | 0.008 |
Yes | 98 | 40.1 | (27.8–57.8) | 37.2 | (25.1–55.2) | ||
NA | 12 | 68.9 | (54.4–87.4) | 68.9 | (54.4–87.4) | ||
Breslow thickness | ≤1 mm | 29 | 81.9 | (67.3–99.8) | 70.6 | (53.0–94.0) | 0.000 |
1.01–2.00 mm | 56 | 75.6 | (63.8–89.5) | 75.6 | (63.8–89.5) | ||
2.01–4.00 mm | 164 | 61.9 | (53.4–71.8) | 57.6 | (48.1–68.9) | ||
>4 mm | 199 | 44.3 | (37.2–52.8) | 39.8 | (32.6–48.6) | ||
NA | 25 | 60.8 | (40.8–90.5) | 43.4 | (23.5–80.3) | ||
Size of metastasis in sentinel node | <0.1 mm | 10 | 87.5 | (67.3–100.0) | 87.5 | (67.3–100.0) | 0.009 |
0.1–1.0 mm | 107 | 63.0 | (53.6–74.2) | 57.7 | (47.0–71.0) | ||
>10.0 mm | 246 | 47.3 | (40.3–55.6) | 41.6 | (34.4–50.4) | ||
NA | 110 | 56.8 | (45.3–71.2) | 48.4 | (36.2–64.7) | ||
Localization of metastasis in sentinel node | Subcapsular | 25 | 79.4 | (63.1–100.0) | 79.4 | (63.1–100.0) | 0.060 |
Combined | 165 | 57.8 | (49.7–67.1) | 51.5 | (42.4–62.5) | ||
Parenchymal | 67 | 52.2 | (40.6–67.2) | 44.0 | (32.0–60.6) | ||
Multifocal | 15 | 55.0 | (32.2–93.8) | 55.0 | (32.2–93.8) | ||
Extensive | 75 | 40.8 | (29.8–55.9) | 38.5 | (27.6–53.8) | ||
NA | 126 | 66.8 | (57.5–77.6) | 61.7 | (51.8–73.5) | ||
Presence of non-sentinel node metastases | No | 341 | 63.9 | (58.2–70.2) | 59.6 | (53.5–66.3) | 0.000 |
Yes | 132 | 41.4 | (32.9–52.2) | 34.7 | (25.9–46.6) | ||
LND basin | Axillary | 261 | 56.4 | (49.8–64.0) | 49.5 | (42.1–58.1) | 0.316 |
Neck | 3 | 50.0 | (12.5–100.0) | 50.0 | (12.5–100.0) | ||
Inguinal | 174 | 63.0 | (55.4–71.5) | 59.0 | (51.2–68.1) | ||
Other | 35 | 28.9 | (14.3–58.6) | 28.9 | (14.3–58.6) | ||
Number of metastatic nodes | 1 | 259 | 66.3 | (60.0–73.3) | 62.7 | (55.9–70.3) | 0.000 |
2–3 | 150 | 48.6 | (40.0–59.0) | 44.5 | (35.7–55.3) | ||
>3 | 50 | 38.2 | (26.0–56.0) | 24.3 | (13.5–43.8) | ||
NA | 14 | 0.0 | (63.3–100.0) | 0.0 | (63.3–100.0) | ||
All patients | 473 | 57.3 | (52.3–62.7) | 52.3 | (47.0–58.1) | 0.000 | |